Bioasis Announces Shares for Debt Transaction
10 févr. 2021 19h02 HE
|
Bioasis Technologies Inc.
NEW HAVEN, Conn., Feb. 10, 2021 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 ™...
Bioasis Announces $200,000 Non-Brokered Private Placement
29 janv. 2021 16h05 HE
|
Bioasis Technologies Inc.
GUILFORD, Conn., Jan. 29, 2021 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 ™...
Bioasis Announces Filing of Its Quarter and Financial Statements and MD&A for the Period Ending November 30, 2020
27 janv. 2021 16h05 HE
|
Bioasis Technologies Inc.
GUILFORD, Conn., Jan. 27, 2021 (GLOBE NEWSWIRE) -- Bioasis Technologies Inc. (TSX.V:BTI; OTCQB:BIOAF) (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company...
Bioasis Announces Stock Option Grant
22 janv. 2021 09h19 HE
|
Bioasis Technologies Inc.
GUILFORD, Conn., Jan. 22, 2021 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3™...
Bioasis to Present at Upcoming Industry Conferences
04 janv. 2021 16h05 HE
|
Bioasis Technologies Inc.
GUILFORD, Conn., Jan. 04, 2021 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. – Bioasis Technologies Inc. (TSX.V:BTI; OTCQB:BIOAF) (the “Company” or “Bioasis”), a pre-clinical, research-stage...
Bioasis Announces Annual General Meeting Results
10 déc. 2020 16h05 HE
|
Bioasis Technologies Inc.
GUILFORD, Conn., Dec. 10, 2020 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC–Bioasis Technologies Inc. (TSX.V:BTI; OTCQB:BIOAF) (the “Company” or “Bioasis”), a pre-clinical, research-stage...
Bioasis Announces Annual General Meeting Details
10 nov. 2020 16h05 HE
|
Bioasis Technologies Inc.
GUILFORD, Conn., Nov. 10, 2020 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC–Bioasis Technologies Inc. (TSX.V:BTI; OTCQB:BIOAF) (the “Company” or “Bioasis”), a pre-clinical, research-stage...
Bioasis Announces Sale of Royalty Interest in Lysosomal Storage Disorder Enzymes Being Developed Under the Chiesi Group–Bioasis Strategic Alliance to XOMA Corporation
03 nov. 2020 16h05 HE
|
Bioasis Technologies Inc.
GUILFORD, Conn., Nov. 03, 2020 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC–Bioasis Technologies Inc. (TSX.V:BTI; OTCQB:BIOAF) (the “Company” or “Bioasis”), a pre-clinical, research-stage...
Bioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending August 31, 2020
29 oct. 2020 16h58 HE
|
Bioasis Technologies Inc.
GUILFORD, Conn., Oct. 29, 2020 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (TSXV:BTI.V; OTCQB:BIOAF), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company...
Bioasis Announces Analyst Coverage Initiated by Zacks Investment Research
22 oct. 2020 16h05 HE
|
Bioasis Technologies Inc.
GUILFORD, Conn., Oct. 22, 2020 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company...